Mitotech S.A. has begun enrollment in VISTA-2, a phase 3 clinical trial of SkQ1, a dry eye disease treatment candidate, according to a press release.
SkQ1, a cardiolipin peroxidation inhibitor, addresses dry eye by acting on the mitochondria at a cellular level, the release said.
The phase 3 trial builds on positive results from the VISTA-1 multicenter, randomized, double-masked, placebo-controlled study, in which SkQ1 demonstrated broad action in the intent to treat group, even though primary endpoints of that trial were not met.
In VISTA-1, SkQ1 showed statistically significant reduction of
Uncategorized